Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Hyalgan®
(sodium hyaluronate) Intra-Articular Injection
CAUTION
Federal law restricts this device to sale by or on the order of a physician.
Hyalgan® is a viscous solution consisting of a high molecular weight (500,000-730,000 daltons) fraction of purified natural sodium hyaluronate (Hyalectin®) in buffered physiological sodium chloride, having a pH of 6.8-7.5. The sodium hyaluronate is extracted from rooster combs. Hyaluronic acid is a natural complex sugar of the glycosaminoglycan family and is a long-chain polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine.
Hyalgan® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy, and to simple analgesics, e.g., acetaminophen.
No information provided.
Hyalgan® is supplied as a sterile, non-pyrogenic solution in 2 mL vials or 2 mL pre-filled syringes.
Each vial or syringe contains:
Sodium Hyaluronate 20.0 mg
Sodium chloride 17.0 mg
Monobasic sodium phosphate • 2H20 0.1 mg
Dibasic sodium phosphate • 12H20 1.2 mg
Water for injection q.s.* to 2.0 mL
*q.s. = up to
Hyalgan® is administered by intra-articular injection. A treatment cycle consists of five injections given at weekly intervals. Some patients may experience benefit with three injections given at weekly intervals. This has been noted in studies reported in the literature in which patients treated with three injections were followed for 60 days.
Precaution: Do not use Hyalgan® if the package is opened or damaged. Store in the original packaging (protected from light) below 77° F (25° C). DO NOT FREEZE.
Precaution: Strict aseptic administration technique must be followed.
Warning: Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronic acid can precipitate in their presence.
Inject subcutaneous lidocaine or similar local anesthetic prior to injection of Hyalgan®.
Precaution: Remove joint effusion, if present, before injection of Hyalgan®.
Do not use the same syringe for removing joint effusion and for injecting Hyalgan®.
Take care to remove the tip cap of the syringe and needle aseptically.
Inject Hyalgan® into the joint through a 20-gauge needle.
Precaution: The vial/syringe is intended for single use. The contents of the vial must be used immediately once the container has been opened. Discard any unused Hyalgan®. Inject the full 2 mL in one knee only. If treatment is bilateral, a separate vial should be used for each knee.
REFERENCES
1. M. Carrabba et a l., 1991 Hyaluronic acid sodium salt (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: a controlled trial versus Orgotein, Final Report, April 1991. Data on file.
2. M. Carrabba et a l., 1995. Effectiveness and safety of 1, 3 and 5 injections of 20 mg/2 ml Hyalgan® in comparison with a placebo and with arthrocentesis only, in the treatment of knee osteoarthritis. European Journal of Rheumatology and Inflammation 15:25-31.
3. M. Dougados et al., 1993. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a one-year placebo-controlled trial. Osteoarthritis and Cartilage 1:97-103.
4. R. Kotz and G. Kolarz, 1997 published as R. Kotz and G. Kolarz, 1999. Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. The American Journal of Orthopedics, 28:5-7.
5. G. Leardini et a l., 1987. Intra-articular sodium hyaluronate (Hyalgan®) in gonarthrosis. Clinical Trials Journal 24(4):341-350.
6. J.J. Scali, 1995. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a longterm study 15(1 ):57-62.
MANUFACTURED BY: Fidia Farmaceutici S.p.A., Via Ponte della Fabbrica 3/A - 35031 Abano Terme, Padua (PD), Italy. MANUFACTURED FOR: Fidia Pharma USA Inc., Parsippany, NJ 07054. Revised May 2014
Hyalgan® was investigated in a pivotal clinical investigation conducted in the United States in which there were three arms (164 subjects treated with Hyalgan®; 168 with placebo; and 163 with naproxen) (refer to Table 1). Common adverse events reported for the Hyalgan®-treated subjects were gastrointestinal complaints, injection site pain, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache. Swelling and effusion, local skin reactions (ecchymosis and rash), and headache occurred at equal frequency in the Hyalgan®- and placebo-treated groups. Hyalgan® treated subjects had 48/164 (29%) incidents of gastrointestinal complaints that were not statistically different from the placebo-treated group. A statistically significant difference in the occurrence of pain at the injection site was noted in the Hyalgan®-treated subjects: 38/164 (23%) in comparison to 22/168 (13%) in the placebo-treated subjects (p = 0.022). There were 6/164 (4%) premature discontinuations in Hyalgan®-treated subjects due to injection site pain in comparison to 1/168 ( < 1%) in the placebo-treated subjects. These differences were not statistically significant. Two (2/164, 1.2%) Hyalgan®-treated subjects and 3/168 (1.8%) placebo-treated subjects were reported to have positive bacterial cultures of effusion aspirated from the treated knee. The two Hyalgan®-treated subjects and two of the placebo-treated subjects did not exhibit evidence of infection clinically or subsequently and were not treated with antibiotics. One of the placebo-treated subjects was hospitalized and received presumptive treatment for septic arthritis.
Hyalgan® has been in clinical use in Europe since 1987. Analysis of the adverse events that have been reported with the use of Hyalgan® in Europe reveals that most of the events are related to local symptoms such as pain, swelling/effusion, and warmth or redness at the injection site. Usually such symptoms disappear within a few days by resting the affected joint and applying ice locally. Only sporadically have these events been more severe and longer lasting. Very rare cases of intra-articular infection have been reported. Strict aseptic technique must be followed in administering Hyalgan®. Systemic allergic reactions rarely have been recorded. Isolated cases of an anaphylactic or anaphylactic-like reaction have been reported in post-marketing experience and they all resolved. Allergic-type signs and symptoms such as rash, pruritus, and urticaria also are very rare. A few cases of fever were reported. In some instances, they were associated with local reactions, in other cases, no association other than temporal was found with the use of the product.
Adverse experience data from the literature contain no evidence of increased risk relating to retreatment with Hyalgan®. The frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle. (Carrabba et al., 1995; Carrabba et al., 1991; Kotz and Kolarz, 1999; Scali, 1995).
No information provided.
Reproductive toxicity studies, including multigeneration studies, have been performed in rats and rabbits at doses up to 11 times the anticipated human dose (1.43 mg/kg per treatment cycle) and have revealed no evidence of impaired fertility or harm to the experimental animal fetus due to intra-articular injections of Hyalgan®. Animal reproduction studies are not always predictive of human response. The safety and effectiveness of Hyalgan® have not been established in pregnant women.
It is not known if Hyalgan® is excreted in human milk. The safety and effectiveness of Hyalgan® have not been established in lactating women.
The safety and effectiveness of Hyalgan® have not been demonstrated in children.
No information provided.
The use of Hyalgan® as a treatment for pain in OA of the knee was investigated in a multicenter clinical trial conducted in the United States.
This study was a double-masked, placebo and naproxen-controlled, multicenter prospective clinical trial with three treatment arms, as summarized in Table 2. A total of 495 subjects with moderate to severe pain was randomized (at baseline evaluation) into three treatment groups in a ratio of 1:1:1 Hyalgan®, placebo, or naproxen.
TABLE 2 STUDY DESIGN
| Routes of Administration | Hyalgan® | Placebo | Naproxen |
| S.C. i.a.* p.o./b.i.d. p.o./p.r.n. (not to exceed 4 grams/day) | Lidocaine (1%) Hyalgan® (20 mg/2 mL) Placebo for naproxen capsules Acetaminophen | Lidocaine (1%) Phosphate-Buffered Saline (2 mL) Placebo for naproxen capsules Acetaminophen | Lidocaine (1%) none Naproxen capsules (500 mg) Acetaminophen |
| Legend: s.c. = subcutaneous; i.a. = intra-articular; p.o.
= by mouth; b.i.d. = twice a day; p.r.n. = as needed * Synovial fluid was aspirated (when present) in the Hyalgan® and placebo groups. |
|||
The demographics of trial participants were comparable across treatment groups with regard to age, sex, race, height, weight, history of osteoarthritis, prior use of NSAIDs, prior physical therapy, and use of assistive devices (refer to Table 3).
After meeting initial screening requirements NSAID therapy was discontinued. After 2 weeks, all subjects returned for baseline evaluations. The baseline evaluation included assessment of three primary effectiveness criteria; measurement of pain during a 50-foot walk test using a 100 mm Visual Analog Scale (VAS), a categorical assessment (0 = none to 5 = disabled) of pain, as assessed by a masked evaluator, during the 48 hours preceding the visit, and a categorical assessment (0 = none to 5 = disabled) of pain, as assessed by the subject, during the 48 hours preceding the visit.
All subjects who completed the NSAID washout period and met all entry requirements received their first injection after randomization.
All subjects received subcutaneous lidocaine injections.
Intra-articular injections (Hyalgan®, placebo) were administered weekly for a total of 5 injections (Weeks 0-^4). The naproxen group received 500 mg of naproxen to be taken b.i.d. for 26 weeks.
Subsequent visits and evaluations took place at Weeks 5, 9, 1 2 ,1 6 , 21, and 26. Safety and effectiveness criteria were assessed and recorded at these time periods.
For this trial, overall success for effectiveness was defined as meeting all four of the success criteria listed in Table 4 using scores from week 26. The criteria were met (refer to Tables 4 through 8).
Three randomized, controlled clinical investigations were performed that provide information about a three-injection treatment course of Hyalgan®. In all of the studies the patients were followed for 60 days.
Two studies provided a comparison to placebo. One of the placebo-controlled studies evaluated two treatment doses of Hyalgan®, 20 mg/2 ml and 40 mg/2 ml. The 20 mg/2 ml treatment arm included 19 knees, the 40 mg/2 ml included 20 knees, and the placebo arm included 18 knees.
The other placebo study included 20 knees in the treatment group and 18 knees in the placebo-treatment group. The third study provided a comparison between patients treated with three weekly injections of Hyalgan® followed by 2 weekly treatments with arthrocentesis with patients treated with arthrocentesis for five weeks, and arthrocentesis and placebo injections for five weeks. Additional arms of this study assessed additional treatment regimens. Statistical evaluation of the data was performed at day 60. In this study, only patients considered to be success were followed beyond day 60. These patients were followed for 180 days, however, due to the number of dropouts, statistical evaluation was not performed on data gathered at time points beyond day 60. The results of these investigations reported that the three-injection Hyalgan® treated patients experienced pain relief beginning at day 21 and continuing throughout the remaining 60-day observation period.
In order for the product to be considered safe, the incidence of severe swelling and pain consequent to intra-articular injection should be less than 5%. This criterion was met as indicated in Table 1. See the Adverse Events Section.
TABLE 1: Incidence1 of Adverse Events Occurring in
More than 5% of All Subjects
| Adverse Event | Hyalgan® N = 164 |
Placebo N = 168 |
| Gastrointestinal Complaints2 | 48 (29%) | 59 (36%) |
| Injection site pain3 | 38 (23%)4 | 22(13%) |
| Headache | 30(18%) | 29(17%) |
| Local skin5 | 23 (14%) | 17(10%) |
| Local joint pain and swelling6 | 21 (13%) | 22(13%) |
| Pruritus (local) | 12(7%) | 7(4%) |
| Notes: 1Numberand %of subjects 2vere in 4 Hyalgan' -treated subjects and 4 placebo-treated subjects 3Severe in 5 Hyalgan'-treated subjects and 2 placebo-treated subjects 4Statistically significant (p=0.02) 5includes ecchymosis and rash 6Severe in 2 Hyalgan”-treated subjects (1.2%) and 1 placebo-treated subject |
||
TABLE 3: Demographic Characteristics of all
randomized subjects
| DEMOGRAPHIC VARIABLE | TREATMENT | TOTAL N =495 |
||
| Hyalgan® N = 164 |
Placebo N = 168 |
Naproxen N = 163 |
||
| AGE (years): | ||||
| Mean | 63.5 | 643 | 63.2 | 63.7 |
| SD | 10.1 | 10.0 | 92 | 9.8 |
| Range | 41-90 | 44-85 | 40-80 | 40-90 |
| Gender [N (96)]: | ||||
| Female | 99 (603) | 91 (54.1) | 99(60.7) | 289 (58.4) |
| Male | 65(39.6) | 77 (45.8) | 64 (39.3) | 206(41.6) |
| Race [N (%)]: | ||||
| Caucasian | 137(83.6) | 135 (80.4) | 133(81.6) | 405(81.8) |
| Black | 23 (14.0) | 32(19.0) | 25(15.3) | 80 (16.2) |
| Other | 4(4.2) | 1 (1.0) | 5(3.1) | 10(2.0) |
| Height (cm): | ||||
| Mean | 167.8 | 168.6 | 167.6 | 168.0 |
| SD | 8.8 | 10.7 | 11.9 | 10.5 |
| Range | 145-190 | 142-193 | 102-198 | 102-198 |
| Weight (kg): | ||||
| Mean | 88.4 | 88.1 | 89.7 | 88.7 |
| SD | 18.0 | 18.2 | 18.4 | 18.2 |
| Range | 46-139 | 49-170 | 45-150 | 45-170 |
| NSAIDs Use | 107(65.2) | 117(69.6) | 113(69.3) | 337 (68.1) |
| (N,W) | ||||
| Use of Assistive | 35(213) | 34 (20.2) | 32(19.6) | 101 (20.4) |
| Devices (N, %) | ||||
| Physical Therapy (N, 34) | 20 (12.2) | 17 (10.1) | 25(153) | 62 (12.5) |
| Legend: cm = centimeters; kg = kilograms; SD = standard deviation | ||||
TABLE 4: Clinical Results
| Evaluation | Success Criteria | Results |
| 100 mm VAS for pain during 50 foot walk. | A statistically significant (alpha = 0.05) reduction on mean VAS for Hyalgan® when compared to placebo at Week 26. This difference was also to exceed one fourth of the Standard Deviation of the mean change from baseline. | At Week 26, the difference between the Hyalgan*-treated group and the placebo-treated group adjusted means was 8.85 mm (p = 0.0043), which is a difference of approximately one-third of a standard deviation (Table 5). |
| Masked Evaluator Categorical Assessment of subject pain (0=none to 5=disabled) during the 48 hours preceding visits. | The number of Hyal^n®-treated subjects showing improvement at Week 26 was to be concordant with the VAS results, however, not required to be independently statistically significant | At Week 26 the masked evaluator's categorical assessment of pain indicated that the Hyalgan®-treated subjects experienced less pain than the placebo-treated subjects (Table 6). |
| Subjects' Categorical Assessment of pain (0=none to 5=disabled) during the 48 hours preceding visits. | The number of Hyalgan®-treated subjects showing improvement at Week 26 was to be concordant with the VAS results; however, not required to be independently statistically significant | At Week 26 the subjects’ categorical assessment of pain indicated that the Hyalgan®-treated subjects experienced less pain than the placebo-treated subjects (Table 7). |
| Magnitude of the observed effect for Hyalgan® versus placebo on both the VAS and the categorical pain assessments. | At Week 26 the magnitude of the observed effect for Hyalgan® versus placebo on both the VAS and the categorical pain assessments were to beat least 50% of those observed for the naproxen group. | The improvement in pain on the VAS exhibited by the Hyalgan“-treated group relative to the placebo-treated group were at least 5096 of the benefits exhibited by the naproxen-treated group relative to the placebo-treated group. The results of the categorical assessments by the masked evaluator and the subject indicated that improvement of the Hyalgan*-treated group relative to the placebo-treated group was at least 50% of the benefits exhibited by the naproxen-treated group relative to the placebo-treated group (Table 8). |
TABLE 5: ANCOVA of 50-Foot Walk Test (mm) VAS by Week
for all Completed Subjects
| Week | ||||||||
| 3 | 4 | 5 | 9 | 12 | 16 | 21 | 26 | |
| Adjusted Means Hyalgan® | 27.23 | 21.54 | 19.29 | 20.04 | 20.26 | 20.83 | 18.44 | 17.88 |
| Placebo | 32.35 | 28.57 | 25.67 | 24.28 | 26.66 | 25.44 | 24.77 | 26.73 |
| Hyalgan® versus Placebo | 5.13 | 7.03 | 6.39 | 4.24 | 6.40 | 4.61 | 6.33 | 8.846 |
| p-value | 0.06 | 0.01 | 0.01 | 0.1 | 0.03 | 0.1 | 0.02 | 0.004 |
TABLE 6: Masked Evaluators' Categorical Assessments of
Pain for Completed Subjects in Prior 48 Hours: Level of Pain by Treatment Group
at Baseline and Week 26
| NUMBER (%) OF SUBJECTS IN CATEGORY | ||||||
| Hyalgan® | Placebo | Naproxen | ||||
| Baseline | Week 26 | Baseline | Week 26 | Baseline | Week 26 | |
| None (0) | 0(0.0) | 27(25.7) | 0 (0.0) | 15(13.0) | 0 (0.0) | 17(15.0) |
| Slight (1) | 1 (1.0) | 23(21.9) | 0 (0.0) | 27(23.5) | 0(0.0) | 32 (28.3) |
| Mild (2) | 2(1.9) | 24 (22.9) | 2(1.7) | 29 (25.2) | 2(1.8) | 27(23.9) |
| Moderate 3) | 69(65.7) | 26 (24.8) | 85(73.9) | 34 (29.6) | 79(70.5) | 28 (24.8) |
| Marked (4) | 33(31.4) | 5(4.8) | 28 (24.3) | 10(8.7) | 31 (27.7) | 9 (8.0) |
| TOTAL | 105(100) | 105(100) | 115(100) | 115(100) | 112* (100) | 113(100) |
| *One Naproxen treated subject was missing a Baseline assessment | ||||||
TABLE 7: Subjects' Categorical Assessments of Pain for
Completed Subjects in Prior 48 Hours: Level of Pain by Treatment Group at
Baseline and Week 26
| NUMBER (%) OF SUBJECTS IN CATEGORY | ||||||
| Hyalgan® | Placebo | Naproxen | ||||
| Baseline | Week26 | Baseline | Week26 | Baseline | Week26 | |
| None (0) | 1 (1.0) | 23(21.9) | 0 (0.0) | 14 (12.2) | 0 (0.0) | 13(11.5) |
| Slight (1) | 2(1.9) | 27(25.7) | 0 (0.0) | 24 (20.9) | 1 (0.9) | 31 (27.4) |
| Mild (2) | 6(5.7) | 19(18.1) | 8(7.0) | 24 (20.9) | 7(6.2) | 26 (23.0) |
| Moderate (3) | 62 (59.0) | 26 (24.8) | 78 (67.8) | 40 (34.8) | 72 (63.7) | 31 (27.4) |
| Marked (4) | 34 (32.4) | 10(9.5) | 29(25.2) | 13(11.3) | 33 (29.2) | 12(10.6) |
| TOTAL | 105(100) | 105(100) | 115(100) | 115(100) | 113 (100) | 113 (100) |
TABLE 8: Hyalgan* Effect as a Percentage of the
Naproxen-Placebo Difference
| Assessment | Hyalgan® (HYL) | Placebo (PLA) | Naproxen (NAP) | HYL-PLA | NAP-HYL | NAP-PLA | (HYL-PLA) %of (NAP-PLA) |
| VAS for 50 foot Walk Baseline Adjusted Mean Effect Sizes From ANCOVA | -8.85 mm on a 100 mm VAS | 4,12 mm on a 100 mm VAS | -4.73* mm on a 100 mm VAS | 187% | |||
| % of Subjects Improved by Masked Evaluators | 78.1 | 69.6 | 73.2 | 8.5 | -4.9 | 3.6 | 236% |
| % of Subjects Improved by Subjects | 733 | 62.6 | 67.3 | 10.7 | -6.0 | 4.7 | 228% |
| *Imputed as (NAP-HYL)+(HYL-PLA). Note that Effectiveness Success Criterion D is satisfied since ((HYL-PLA) % of (NAP-PLA)) > 50% for all three of the above pain assessments. |
|||||||
No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.
